Article Text

Download PDFPDF
Continued escitalopram reduces risk of relapse in people with generalised social anxiety disorder

Statistics from

OpenUrlCrossRefPubMedWeb of Science

Q Does continuing escitalopram treatment reduce relapse rates in people with generalised social anxiety disorder?


Embedded ImageDesign:

Open label followed by randomised controlled trial.

Embedded ImageAllocation:


Embedded ImageBlinding:

Double blinded in randomised controlled phase.

Embedded ImageFollow up period:

Twenty four weeks.

Embedded ImageSetting:

Seventy six centres in 11 countries (Canada, South Africa, and several countries in Europe) from January 2001 to June 2002.

Embedded ImagePatients:

517 people with generalised social anxiety disorder (DSM-IV) aged 18–80 years entered into the open label phase. Inclusion criteria included: a score greater than 70 on the Leibowitz Social Anxiety Scale (LSAS), fear and/or avoidance behaviours in at least four social situations and a score greater than five on at least 1 of the subscales of the Sheehan Disability …

View Full Text


  • For correspondence: Stuart A Montgomery, MD, PO Box 8751, London W13 8WH, UK; Stuart{at}

  • Source of funding: H Lundbeck A/S.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.